Bavarian Nordic A/S makes the following changes to the Company's Articles of Association, based on Board decision of 2 May 2007. Bavarian Nordic A/S has decided to increase its share capital with a total number of 164,152 shares with a nominal value DKK 10 per share as a consequence of exercise of warrants by Directors, management and employees in the Company and its subsidiaries. Of the new shares, 155,603 are subscribed to at DKK 283 per share and 8,549 are subscribed to at DKK 437 per share. The proceeds for the company amount to DKK 47,771,562. The new shares will be listed on the Copenhagen Stock Exchange once registered with the Danish Commerce and Companies agency. After the increase of share capital Article 4 of the Articles of Association shall read: New shares as shall have the same rights as existing shares pursuant to the Articles of Association, according to which new shares shall be negotiable securities and shall be issued to the holder but can be registered by name in the Company's register of shareholders. No limitations in the negotiability of the new shares shall apply, and no duty for redemption shall be attached hereto. From the time of subscription the shares shall have pre-emptive rights to new shares and have voting right. The shares shall be eligible for dividends for the current year. “Article 4 The Company's share capital amounts to 78,155,680, in words Seventyeightmilliononehundredfiftyfivethousandsixhundredeighty 00/100 Danish kroner, divided into shares in the denomination of DKK 10 and multiples thereof. The share capital has been paid up in full.” As a consequence of the exercise of warrants Articles 5c, 5d and 5e and exhibits 1, 2 and 3 shall be deleted. Kvistgård, 2 May 2007 Asger Aamund Chairman Contacts: Peter Wulff, President & CEO Telephone: +45 33 26 83 83 About Bavarian Nordic A/S: Bavarian Nordic (CSE: BAVA) is a leading international biopharmaceutical company developing and producing innovative vaccines to prevent and treat infectious diseases and cancer. With operations in Denmark, Germany, the USA, and Singapore, Bavarian Nordic employs over 200 people. Bavarian Nordic's patented technology, MVA-BN®, is as been demonstrated in clinicial studies, one of the world's safest, multivalent vaccine vectors for the development of vaccines against various infectious diseases such as smallpox, HIV/AIDS, as well as against breast and prostate cancer. Several MVA-BN®-based HIV and smallpox vaccines are in clinical Phase I and Phase II trials. Bavarian Nordic has ongoing development contracts with the US government to develop IMVAMUNE® as a safe third-generation smallpox vaccine. Bavarian Nordic has supplied several other governments with smallpox vaccines. For more information please visit www.bavarian-nordic.com “Safe Harbour" Statement Under the Private Securities Litigation Reform Act of 1995: Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. No "forward-looking statement" can be guaranteed, and actual results may differ materially from those projected. Bavarian Nordic undertakes no obligation to publicly update any "forward-looking statement", whether as a result of new information, future events, or otherwise. Additional information regarding risks and uncertainties is set forth in the current Annual Report, which we incorporate by reference. Stockwise Resumé Bavarian Nordic A/S increases its share capital as a consequence of exercise of warrants
Bavarian Nordic A/S increases its share capital as a consequence of exercise of warrants
| Source: Bavarian Nordic A/S
Attachments
